Organon backs FY23 revenue view $6.15B-$6.25B, consensus $6.22B

Backs FY23 adjusted EBITDA margin view 30.5%-31.5%. FY23 free cash flow before one-time spin-related costs is expected to be above the high end of the previously provided range of $700M to $800M. The company said, “The information presented above reflects the company’s preliminary estimates subject to the completion of the company’s financial closing procedures and any adjustments that may result from the completion of the quarterly and annual review of the company’s consolidated financial statements. Organon will report its full year 2023 results and more fulsome 2024 outlook on February 15, 2024.”